Anna M. Schmoker
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Anna M. Schmoker has a total of 186 co-authors. Here are the top co-authors by number of shared publications:
- Michael J. Eck
Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA 02215, USA
8 shared publications - Hyesung Jeon
Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA 02215, USA
5 shared publications - Bryan A. Ballif
Department of Biology University of Vermont Burlington VT USA
3 shared publications - David A. Scott
Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA 02215, USA
3 shared publications - Nathanael Schiander Gray
Stanford University
3 shared publications - Shaun Rawson
Harvard Cryo-Electron Microscopy Center for Structural Biology, Harvard Medical School
3 shared publications
Latest Publications
- Open Access
- 23 October 2026
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 12 (43) , eaee5241
RAF isoform selectivity of MEK inhibitors and rational design of a covalent ARAF-MEK inhibitor
Aberrant activation of the RAS/RAF/mitogen-activated protein kinase kinase (MEK)/extracellular signal–regulated kinase pathway is a frequent cause of cancer. Allosteric MEK inhibitors block this pathway by binding RAF-MEK complexes to prevent activation of MEK by RAF. However, how MEK inhibitor potency varies across the three RAF isoforms remains poorly understood. We profiled seven allosteric MEK inhibitors and observed a notable hierarchy of sensitivity: All most potently inhibited CRAF-driven MEK activation while relatively sparing ARAF-driven activation. We identified point mutations in ARAF and CRAF proximate to the MEK inhibitor binding site that markedly altered inhibitor sensitivity. Using a rational design approach, we developed a more potent inhibitor of ARAF-driven MEK signaling, TWG-07-148. Our cryo–electron microscopy structure shows how this acrylamide-containing analog of MEK inhibitor trametinib covalently targets Cys 514 , a residue unique to ARAF. Our studies highlight the importance of the activating RAF isoform as a determinant of MEK inhibitor sensitivity and provide proof of concept for the development of MEK inhibitors that more effectively block ARAF-driven MEK signaling via covalent targeting of Cys 514 .
- 23 October 2026
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 12 (43) , eaee5241
Open AccessRAF isoform selectivity of MEK inhibitors and rational design of a covalent ARAF-MEK inhibitor
Aberrant activation of the RAS/RAF/mitogen-activated protein kinase kinase (MEK)/extracellular signal–regulated kinase pathway is a frequent cause of cancer. Allosteric MEK inhibitors block this pathway by binding RAF-MEK complexes to prevent activation of MEK by RAF. However, how MEK inhibitor potency varies across the three RAF isoforms remains poorly understood. We profiled seven allosteric MEK inhibitors and observed a notable hierarchy of sensitivity: All most potently inhibited CRAF-driven MEK activation while relatively sparing ARAF-driven activation. We identified point mutations in ARAF and CRAF proximate to the MEK inhibitor binding site that markedly altered inhibitor sensitivity. Using a rational design approach, we developed a more potent inhibitor of ARAF-driven MEK signaling, TWG-07-148. Our cryo–electron microscopy structure shows how this acrylamide-containing analog of MEK inhibitor trametinib covalently targets Cys 514 , a residue unique to ARAF. Our studies highlight the importance of the activating RAF isoform as a determinant of MEK inhibitor sensitivity and provide proof of concept for the development of MEK inhibitors that more effectively block ARAF-driven MEK signaling via covalent targeting of Cys 514 .
- Open Access
Glycogen Synthase Kinase-3β Regulates Cellular Prion Protein Levels
The normal cellular prion protein (PrPC) is an essential substrate in all forms of prion diseases and a receptor for Aβ oligomers in Alzheimer’s disease. However, it is not fully understood how cells regulate PrPC levels. Recently, we identified glycogen synthase kinase-3β (GSK-3β) as a potential regulator of PrPC levels in a whole genome knockout screen. Here, we show that both cell surface and total PrPC levels can be reduced either by siRNA-mediated Gsk3b (but not Gsk3a) knockdown or by CRISPR-mediated Gs3b knockout. Whole cell mass spectrometric analysis showed that PrPC was the 60th most significantly reduced protein (out of 7227 total proteins detected) in Gsk3b knockout cells, compared to wild-type cells. Two different GSK-3 inhibitors, laduviglusib (CHIR-99021) and AZD-1080, reduced PrPC levels in mouse CAD5 and human BE(2)-C cells, both in undifferentiated and differentiated states. PrPC levels were similarly reduced by cycloheximide treatment in both Gsk3b knockout and WT cells, indicating that GSK-3β regulates PrPC levels through a post-translational mechanism. Finally, treatment with either laduviglusib or AZD-1080 reduced PrPSc levels in CAD5 cells infected with three different rodent prion strains. Overall, the results reveal that GSK-3β activity controls PrPC levels in living cells, revealing a novel regulatory mechanism and promising therapeutic target.
Open AccessGlycogen Synthase Kinase-3β Regulates Cellular Prion Protein Levels
The normal cellular prion protein (PrPC) is an essential substrate in all forms of prion diseases and a receptor for Aβ oligomers in Alzheimer’s disease. However, it is not fully understood how cells regulate PrPC levels. Recently, we identified glycogen synthase kinase-3β (GSK-3β) as a potential regulator of PrPC levels in a whole genome knockout screen. Here, we show that both cell surface and total PrPC levels can be reduced either by siRNA-mediated Gsk3b (but not Gsk3a) knockdown or by CRISPR-mediated Gs3b knockout. Whole cell mass spectrometric analysis showed that PrPC was the 60th most significantly reduced protein (out of 7227 total proteins detected) in Gsk3b knockout cells, compared to wild-type cells. Two different GSK-3 inhibitors, laduviglusib (CHIR-99021) and AZD-1080, reduced PrPC levels in mouse CAD5 and human BE(2)-C cells, both in undifferentiated and differentiated states. PrPC levels were similarly reduced by cycloheximide treatment in both Gsk3b knockout and WT cells, indicating that GSK-3β regulates PrPC levels through a post-translational mechanism. Finally, treatment with either laduviglusib or AZD-1080 reduced PrPSc levels in CAD5 cells infected with three different rodent prion strains. Overall, the results reveal that GSK-3β activity controls PrPC levels in living cells, revealing a novel regulatory mechanism and promising therapeutic target.
- Open Access
- 22 June 2026
- Published by Wiley in FEBS Letters
ABL kinase‐dependent phosphorylation of SH proteins promotes their direct interaction with CRK family SH2 domains
CT10 regulator of kinase (CRK) and CRK‐Like (CRKL) are important Src homology 2 (SH2)‐ and SH3‐domain containing signaling adaptors, which drive cell adhesion, motility, differentiation, and proliferation. Their genetically defined and overlapping roles include facilitating proper development of the vertebrate central nervous system. All four members of the SH2‐domain containing (SH) protein family are enriched in YXXP motifs, which when the initial tyrosine is phosphorylated form the preferred binding motif of CRK family SH2 domains. We show that ABL kinase drives tyrosine phosphorylation of SH protein YXXP motifs and induces their direct binding to the SH2 domains of CRK family adaptors. The implications of the interactions between CRK/CRKL and SH proteins include signal attenuation and relocation of CRK adaptor signaling.
- 22 June 2026
- Published by Wiley in FEBS Letters
Open AccessABL kinase‐dependent phosphorylation of SH proteins promotes their direct interaction with CRK family SH2 domains
CT10 regulator of kinase (CRK) and CRK‐Like (CRKL) are important Src homology 2 (SH2)‐ and SH3‐domain containing signaling adaptors, which drive cell adhesion, motility, differentiation, and proliferation. Their genetically defined and overlapping roles include facilitating proper development of the vertebrate central nervous system. All four members of the SH2‐domain containing (SH) protein family are enriched in YXXP motifs, which when the initial tyrosine is phosphorylated form the preferred binding motif of CRK family SH2 domains. We show that ABL kinase drives tyrosine phosphorylation of SH protein YXXP motifs and induces their direct binding to the SH2 domains of CRK family adaptors. The implications of the interactions between CRK/CRKL and SH proteins include signal attenuation and relocation of CRK adaptor signaling.
- Open Access
- 18 June 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1)
A functional map of phosphoprotein phosphatase regulation identifies an evolutionarily conserved reductase for the catalytic metal ions
Serine/threonine phosphoprotein phosphatases (PPPs) are conserved metalloenzymes and key regulators of intracellular signaling. Here, we systematically map the components and residues required for PP2A-like phosphatase (PP2A/PP4/PP6) function using genome-wide CRISPR knockout and focused base editing screens and provide this as a comprehensive resource. We uncover the reductase CYB5R4 as an evolutionarily conserved activator of PP4 and PP6, but not PP2A. We demonstrate that PP4 and PP6 are redox sensitive and require CYB5R4 to reduce the active site metal ions for activation. Mechanistically, this involves the selective binding of PP4 and PP6 through binding elements in the N-terminal tail of CYB5R4 and CYB5R4-bound heme serving as an electron donor for the active site. We further show that this activation is critical for regulating the response to DNA damage. Our work hints that active site metal ion redox regulation mediates crosstalk between the oxidative state of the cell and specific phosphatase activities.
- 18 June 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1)
Open AccessA functional map of phosphoprotein phosphatase regulation identifies an evolutionarily conserved reductase for the catalytic metal ions
Serine/threonine phosphoprotein phosphatases (PPPs) are conserved metalloenzymes and key regulators of intracellular signaling. Here, we systematically map the components and residues required for PP2A-like phosphatase (PP2A/PP4/PP6) function using genome-wide CRISPR knockout and focused base editing screens and provide this as a comprehensive resource. We uncover the reductase CYB5R4 as an evolutionarily conserved activator of PP4 and PP6, but not PP2A. We demonstrate that PP4 and PP6 are redox sensitive and require CYB5R4 to reduce the active site metal ions for activation. Mechanistically, this involves the selective binding of PP4 and PP6 through binding elements in the N-terminal tail of CYB5R4 and CYB5R4-bound heme serving as an electron donor for the active site. We further show that this activation is critical for regulating the response to DNA damage. Our work hints that active site metal ion redox regulation mediates crosstalk between the oxidative state of the cell and specific phosphatase activities.
- Open Access
- 29 May 2026
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 12 (22) , eaeb2368
Metabolic rewiring driven by phosphoglycolate phosphatase deletion inhibits ferroptosis
Modulating ferroptosis, a form of cell death driven by uncontrolled lipid peroxidation, is of interest in numerous diseases. Here, we found that the deletion of phosphoglycolate phosphatase (PGP), an essential enzyme that safeguards high glycolytic flux, suppresses ferroptosis. Using metabolomic and isotopic labeling experiments together with lipid and proteomic profiling, we find that PGP loss drives a rewiring of the pentose phosphate pathway and of cellular energy and lipid metabolism that triggers a multifactorial antioxidant response. Paradoxically, our attempts to block PGP pharmacologically led to the realization that the recently described PGP inhibitor compound 1 (CP1) exerts a strong ferroptosis-sensitizing effect. Using genetic, biochemical, and biophysical approaches, we characterize CP1 as a direct, species-independent, dual inhibitor of PGP and ferroptosis suppressor protein 1 (FSP1), and further find that CP1 triggers FSP1 self-assembly. In sum, we identify PGP as a target protein for ferroptosis control and introduce a small-molecule FSP1 inhibitor with unique features to the armamentarium of pharmacological ferroptosis modulators.
- 29 May 2026
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 12 (22) , eaeb2368
Open AccessMetabolic rewiring driven by phosphoglycolate phosphatase deletion inhibits ferroptosis
Modulating ferroptosis, a form of cell death driven by uncontrolled lipid peroxidation, is of interest in numerous diseases. Here, we found that the deletion of phosphoglycolate phosphatase (PGP), an essential enzyme that safeguards high glycolytic flux, suppresses ferroptosis. Using metabolomic and isotopic labeling experiments together with lipid and proteomic profiling, we find that PGP loss drives a rewiring of the pentose phosphate pathway and of cellular energy and lipid metabolism that triggers a multifactorial antioxidant response. Paradoxically, our attempts to block PGP pharmacologically led to the realization that the recently described PGP inhibitor compound 1 (CP1) exerts a strong ferroptosis-sensitizing effect. Using genetic, biochemical, and biophysical approaches, we characterize CP1 as a direct, species-independent, dual inhibitor of PGP and ferroptosis suppressor protein 1 (FSP1), and further find that CP1 triggers FSP1 self-assembly. In sum, we identify PGP as a target protein for ferroptosis control and introduce a small-molecule FSP1 inhibitor with unique features to the armamentarium of pharmacological ferroptosis modulators.
- Open Access
Characterization of Anti-Canine PD-1 Antibodies
Cancer is a leading cause of death in dogs, and incidence rates in dogs exceed those in humans. Current therapeutic options for canine cancer patients remain limited, with most treatments focused on palliative care. Immune checkpoint inhibitors such as anti-PD-1, anti-PD-L1, and anti-CTLA-4 antibodies that have transformed cancer therapy and expanded the therapeutic options in humans could offer the same clinical benefit in canine cancer patients. This study details the engineering and functional characterization of mouse and chimeric mouse–canine anti-canine PD-1 (cPD-1) monoclonal antibodies. We demonstrate that anti-cPD-1 antibodies block the interaction between cPD-1 and its ligand cPD-L1, thereby inhibiting this immune signaling pathway. In a proof-of-concept study in seven companion canine cancer patients, intratumoral therapy with the lead anti-cPD-1 antibody (HugPetmab) was safe, well-tolerated, had no observed adverse events, and showed evidence of tumor control in a subset of injected tumors. These findings support the potential of HugPetmab antibody as an immunotherapeutic option for treating canine cancer patients.
Open AccessCharacterization of Anti-Canine PD-1 Antibodies
Cancer is a leading cause of death in dogs, and incidence rates in dogs exceed those in humans. Current therapeutic options for canine cancer patients remain limited, with most treatments focused on palliative care. Immune checkpoint inhibitors such as anti-PD-1, anti-PD-L1, and anti-CTLA-4 antibodies that have transformed cancer therapy and expanded the therapeutic options in humans could offer the same clinical benefit in canine cancer patients. This study details the engineering and functional characterization of mouse and chimeric mouse–canine anti-canine PD-1 (cPD-1) monoclonal antibodies. We demonstrate that anti-cPD-1 antibodies block the interaction between cPD-1 and its ligand cPD-L1, thereby inhibiting this immune signaling pathway. In a proof-of-concept study in seven companion canine cancer patients, intratumoral therapy with the lead anti-cPD-1 antibody (HugPetmab) was safe, well-tolerated, had no observed adverse events, and showed evidence of tumor control in a subset of injected tumors. These findings support the potential of HugPetmab antibody as an immunotherapeutic option for treating canine cancer patients.
- 21 October 2025
- Published by Elsevier in European Journal of Medicinal Chemistry
- Vol. 302 (Pt 1) , 118274
Allosteric inhibition of JAK2 with lysine-reactive compounds that bind the pseudokinase domain
- 21 October 2025
- Published by Elsevier in European Journal of Medicinal Chemistry
- Vol. 302 (Pt 1) , 118274
Allosteric inhibition of JAK2 with lysine-reactive compounds that bind the pseudokinase domain
- Open Access
- 1 September 2025
- Published by Springer Nature in Nature Communications
- Vol. 16 (1) , 1-14
Cryo-EM structures of CRAF/MEK1/14-3-3 complexes in autoinhibited and open-monomer states reveal features of RAF regulation
CRAF (RAF1) is one of three RAF-family kinases that initiate MAP kinase signaling in response to activated RAS and is essential for oncogenic signaling from mutant KRAS. Like BRAF, CRAF is regulated by 14-3-3 engagement and by intramolecular autoinhibitory interactions of its N-terminal regulatory region. Unlike BRAF, it is thought to require tyrosine phosphorylation in its N-terminal acidic (NtA) motif for full catalytic activation. Here we describe cryo-EM reconstructions of full-length CRAF in complex with MEK1 and a 14-3-3 dimer. These structures reveal a fully autoinhibited conformation analogous to that observed for BRAF and two “open monomer” states in which the inhibitory interactions of the CRD and 14-3-3 dimer are released or rearranged, but the kinase domain remains inactive. Structure-function studies of the NtA motif indicate that phosphorylation or acidic mutations in this segment increase catalytic activity by destabilizing the inactive conformation of the kinase domain. Collectively, these studies provide a structural foundation for understanding the shared and unique regulatory features of CRAF and will inform efforts to selectively block CRAF signaling in cancer.
- 1 September 2025
- Published by Springer Nature in Nature Communications
- Vol. 16 (1) , 1-14
Open AccessCryo-EM structures of CRAF/MEK1/14-3-3 complexes in autoinhibited and open-monomer states reveal features of RAF regulation
CRAF (RAF1) is one of three RAF-family kinases that initiate MAP kinase signaling in response to activated RAS and is essential for oncogenic signaling from mutant KRAS. Like BRAF, CRAF is regulated by 14-3-3 engagement and by intramolecular autoinhibitory interactions of its N-terminal regulatory region. Unlike BRAF, it is thought to require tyrosine phosphorylation in its N-terminal acidic (NtA) motif for full catalytic activation. Here we describe cryo-EM reconstructions of full-length CRAF in complex with MEK1 and a 14-3-3 dimer. These structures reveal a fully autoinhibited conformation analogous to that observed for BRAF and two “open monomer” states in which the inhibitory interactions of the CRD and 14-3-3 dimer are released or rearranged, but the kinase domain remains inactive. Structure-function studies of the NtA motif indicate that phosphorylation or acidic mutations in this segment increase catalytic activity by destabilizing the inactive conformation of the kinase domain. Collectively, these studies provide a structural foundation for understanding the shared and unique regulatory features of CRAF and will inform efforts to selectively block CRAF signaling in cancer.
- Top Cited PapersOpen Access
- 24 July 2025
- Published by Springer Nature in Nature Communications
- Vol. 16 (1) , 1-18
Unveiling the hidden interactome of CRBN molecular glues
Induced proximity by molecular glues refers to strategies that leverage the recruitment of proteins to facilitate their modification, regulation or degradation. As prospective design of molecular glues remains challenging, unbiased discovery methods are necessary to discover new chemical targets. Here we establish a high throughput affinity proteomics workflow leveraging E3 ligase activity-impaired CRBN-DDB1ΔB in cell lysates for the unbiased identification of molecular glue targets. By mapping the interaction landscape of CRBN-binding molecular glues, we unveil 298 protein targets and demonstrate the utility of enrichment methods for identifying targets overlooked by established methods. We use a computational workflow to estimate target confidence and perform biochemical and structural validation of uncharacterized neo-substrates. We further identify a lead compound for the previously untargeted non-zinc finger PPIL4 through a biochemical screen. Our study provides a comprehensive inventory of targets chemically recruited to CRBN and delivers a robust and scalable workflow for identifying drug-induced protein interactions in cell lysates.
- 24 July 2025
- Published by Springer Nature in Nature Communications
- Vol. 16 (1) , 1-18
Top Cited PapersOpen AccessUnveiling the hidden interactome of CRBN molecular glues
Induced proximity by molecular glues refers to strategies that leverage the recruitment of proteins to facilitate their modification, regulation or degradation. As prospective design of molecular glues remains challenging, unbiased discovery methods are necessary to discover new chemical targets. Here we establish a high throughput affinity proteomics workflow leveraging E3 ligase activity-impaired CRBN-DDB1ΔB in cell lysates for the unbiased identification of molecular glue targets. By mapping the interaction landscape of CRBN-binding molecular glues, we unveil 298 protein targets and demonstrate the utility of enrichment methods for identifying targets overlooked by established methods. We use a computational workflow to estimate target confidence and perform biochemical and structural validation of uncharacterized neo-substrates. We further identify a lead compound for the previously untargeted non-zinc finger PPIL4 through a biochemical screen. Our study provides a comprehensive inventory of targets chemically recruited to CRBN and delivers a robust and scalable workflow for identifying drug-induced protein interactions in cell lysates.
- Open Access
- 1 August 2024
- Published by Springer Nature in Research Square
A chaperone-assisted mechanism of outer mitochondrial membrane TOM70 insertion protective against diet-induced obesity
Outer mitochondrial membrane (OMM) proteins communicate with the cytosol and other organelles including the endoplasmic reticulum (ER)1,2. This communication is important in thermogenic adipocytes to increase energy expenditure that controls body temperature and weight3,4. However, the regulatory mechanisms of OMM protein insertion are poorly understood. Herein, stress-induced cytosolic chaperone PPID (peptidyl-prolyl isomerase D/cyclophilin 40/Cyp40) drives OMM insertion of the mitochondrial import receptor TOM70 regulating body temperature and weight in obese mice, and respiratory/thermogenic function in brown adipocytes. PPID PPIase activity and C-terminal tetratricopeptide repeats (TPR), which show specificity towards TOM70 core and C-tail domains, facilitate OMM insertion. Our results provide an unprecedented role for ER-stress-activated chaperones in controlling energy metabolism through a selective OMM protein insertion mechanism with implications in adaptation to cold temperatures and high-calorie diets.
- 1 August 2024
- Published by Springer Nature in Research Square
Open AccessA chaperone-assisted mechanism of outer mitochondrial membrane TOM70 insertion protective against diet-induced obesity
Outer mitochondrial membrane (OMM) proteins communicate with the cytosol and other organelles including the endoplasmic reticulum (ER)1,2. This communication is important in thermogenic adipocytes to increase energy expenditure that controls body temperature and weight3,4. However, the regulatory mechanisms of OMM protein insertion are poorly understood. Herein, stress-induced cytosolic chaperone PPID (peptidyl-prolyl isomerase D/cyclophilin 40/Cyp40) drives OMM insertion of the mitochondrial import receptor TOM70 regulating body temperature and weight in obese mice, and respiratory/thermogenic function in brown adipocytes. PPID PPIase activity and C-terminal tetratricopeptide repeats (TPR), which show specificity towards TOM70 core and C-tail domains, facilitate OMM insertion. Our results provide an unprecedented role for ER-stress-activated chaperones in controlling energy metabolism through a selective OMM protein insertion mechanism with implications in adaptation to cold temperatures and high-calorie diets.